Clinical trials
Angioedemas, Hereditary trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 5 |
| 2024 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 3 |
| Terminated | 3 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ionis Pharmaceuticals, Inc. | 4 |
| KalVista Pharmaceuticals, Ltd. | 4 |
| Pharvaris Netherlands B.V. | 4 |
| Intellia Therapeutics | 3 |
| Pharming Technologies B.V. | 3 |
| Astria Therapeutics, Inc. | 2 |
| CSL Behring | 2 |
| Leiden University Medical Center | 1 |
| Radboud University Medical Center | 1 |
| T. van der Poll | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Angioedemas, Hereditary | 27 |
| Angioedema | 5 |
| Hereditary Angioedema Types I and II | 3 |
| Genetic Diseases, Inborn | 2 |
| Hereditary Angioedema Type III | 2 |
| Inflammation | 2 |
| Sepsis | 2 |
| Asthma | 1 |
| Brain Infarction | 1 |
| Brain Injuries, Traumatic | 1 |
Trials
Showing 51 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.